viewer
The European Union (EU) has decided to strengthen export control of vaccines for novel coronavirus infections (Corona 19) such as AstraZeneca. Conflict between the UK and the EU over securing vaccine supplies is intensifying.
The British Guardian announced on the 23rd (local time) an amendment to the’Vaccine Export Permit System’ that restricts exports to countries where the vaccination rate is high or the spread of infectious diseases is not serious when the EU executive committee, the EU executive branch, decides whether to export individual vaccines. It was reported that it was announced. On the same day, the New York Times of the United States also said that the EU decided to include a revision to restrict the export of corona 19 vaccines for the next six weeks.
The EU has been controlling exports only to manufacturers who have not been able to fill the vaccine volume contracted with the EU since last January, but this amendment has made export licensing standards more stringent.
Analysis said that this measure is aimed at the United States, which is passive in vaccine exports, including the UK, which is in conflict with the EU over securing the vaccine. The EU has been criticizing the UK for not supplying enough AstraZeneca vaccines produced in the country to the EU, and the UK countered that it’has never blocked exports (to the EU)’. With such a heightened nervous war, Ursula Fon der Raien, the head of the EU Commission, warned on the 17th that vaccine exports to the UK could be blocked.
The United States also produces about 27% of the world’s COVID-19 vaccines, including AstraZeneca, Pfizer, Modena, and Johnson & Johnson, but uses most of it for domestic use.
The US Internet media Axios said on the 22nd (local time) that the US makes about 27% of the world’s COVID-19 vaccine production, but the vaccine exports are 0%, and that it is focusing on its national priority vaccination policy. Pointed out. On the other hand, China and India, including the EU, exported half of their vaccine production to foreign countries.
Meanwhile, the Drug Safety Monitoring Committee (DSMB), an independent verification agency in the United States, raised suspicion that the results of a large-scale clinical trial conducted by AstraZeneca in the United States may contain out-of-date information. DSMB said to the US authorities, “If the information is out of date, the efficacy of the vaccine cannot be fully guaranteed.”
/ Reporter Yang-jun Cho [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >